The company's shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

LONDON/COPENHAGEN (Reuters) -Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...